Laprise JF, Chesson HW, Markowitz LE, et al. - Researchers assessed the added population-level effectiveness and cost-effectiveness of extending the US HPV vaccination program to females aged 27-45 years and males aged 22-45 years. They used the HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation), an individual-based transmission dynamic model of HPV infection and correlated diseases, calibrated to age-specific US data for their analysis. Overall, the current HPV vaccination program was prognosticated to be price saving. Moreover, in comparison with current recommendations, extending vaccination to older ages was prognosticated to produce small additional health benefits and result in substantially greater incremental cost-effectiveness ratios.